Biomarker & Molecular Testing in Lymphoma: An Orientation

Why molecular testing matters here

"Lymphoma" is not one disease but a large family of B-cell, T-cell, and NK-cell neoplasms whose behavior ranges from indolent to explosively aggressive. Because these entities can look similar under the microscope, modern classification systems define many of them by their molecular and immunophenotypic signatures rather than by morphology alone [1,2]. The practical consequence is that biomarker testing does three distinct jobs: it establishes the diagnosis and lineage, it refines prognosis, and it increasingly gates access to specific drug classes. A single result — a translocation, a surface antigen, a point mutation — can determine which category a tumor belongs to and, downstream, which therapeutic strategies are even applicable.

The sections below group the provided biomarkers by purpose. Each is named so it can be explored in its own detail article. Throughout, remember that a biomarker result maps to eligibility for a class of therapy — it is never, by itself, a treatment recommendation for any individual.

What gets tested, grouped by purpose

Diagnostic and lineage-defining markers

Several markers exist primarily to tell one entity from another.

• Cyclin D1 / t(11;14) (CCND1) is the defining lesion of mantle cell lymphoma (MCL), separating it from chronic lymphocytic leukemia (CLL) and other CD5-positive small B-cell lymphomas [1,2,3]. Detection uses cyclin D1 IHC and FISH for the IGH::CCND1 fusion.
• SOX11 rescues the diagnosis in the rare cyclin D1-negative MCL cases and additionally helps identify the more indolent, SOX11-negative leukemic non-nodal variant [1,4].
• BCL2 rearrangement / t(14;18) and BCL2 IHC in follicles distinguishes neoplastic follicular lymphoma from reactive follicular hyperplasia — reactive germinal centers are BCL2-negative, making this a diagnostic cornerstone [1,2,5].
• EBV (EBER in situ hybridization) defines or supports several entities, including EBV-positive DLBCL and immune-deficiency/dysregulation-associated large B-cell lymphomas [1,6].
• MYD88 L265P supports the diagnosis of lymphoplasmacytic lymphoma / Waldenström macroglobulinemia (WM) and is also recurrent in immune-privileged-site large B-cell lymphomas [1,7].

Prognostic markers

These stratify expected outcome and often influence how intensively disease is approached.

• Cell-of-origin (Hans algorithm: CD10, BCL6, MUM1) partitions DLBCL into germinal-center B-cell (GCB) and non-GCB subtypes using an IHC surrogate for gene-expression profiling; the non-GCB/ABC group has historically carried a worse outcome [1,8].
• MYC / BCL2 protein co-expression (dual-expressor) identifies an adverse phenotype (MYC ≥40% and BCL2 ≥50% by IHC). Critically, this is not the same as "double-hit," which is genetic — a distinction that causes frequent confusion [1,9].
• Ki-67 proliferation index is a key prognostic grade in MCL; a near-100% index supports Burkitt lymphoma and helps separate aggressive from indolent disease [1,2,10].
• IGHV mutation status is prognostic in CLL, with mutated cases faring more favorably than unmutated ones and response durability differing accordingly [1,11].

Predictive / therapy-gating markers

These connect most directly to drug classes.

• CD20 is the target of the anti-CD20 antibody class; loss of expression (for example, after prior anti-CD20 therapy) has therapeutic implications [1,12].
• CD19 is the target of CD19-directed CAR-T cells and CD19/CD3 bispecific antibodies in relapsed/refractory aggressive B-cell lymphoma; antigen escape is a recognized resistance mechanism [1,13].
• TP53 / del(17p) is an adverse predictor across B-cell lymphomas that, in CLL and MCL, steers away from chemoimmunotherapy and toward targeted agents [1,2,14].
• MYD88 L265P additionally predicts BTK-inhibitor sensitivity in WM, an effect modified by CXCR4 status [1,7].

Markers that serve multiple purposes

MYC / BCL2 / BCL6 rearrangements (FISH) are both diagnostic and prognostic. The combination of MYC plus BCL2 rearrangement now defines the high-grade "double-hit" category (DLBCL/HGBL-MYC/BCL2), an adverse-prognosis group that influences regimen intensity. Under current classifications, MYC with BCL6 only no longer qualifies for this category [1,2,15,16].

How results steer treatment (result → drug class)

The evidence suggests several reasonably durable linkages, all at the level of class eligibility:

• CD20-positive disease → eligibility for the anti-CD20 antibody class [12].
• CD19-positive relapsed/refractory aggressive B-cell lymphoma → eligibility for CD19 CAR-T and CD19/CD3 bispecific classes; documented CD19 loss signals a resistance pathway [13].
• TP53-aberrant CLL or MCL → rationale to favor targeted agents (BTK inhibitors, BCL2 inhibitors) over chemoimmunotherapy [14].
• MYD88 L265P-positive WM → predicted sensitivity to BTK inhibitors, modulated by CXCR4 [7].
• MYC+BCL2 double-hit high-grade lymphoma → an adverse category that informs regimen-intensity decisions [15,16].
• Cyclin D1+/t(11;14)+ → confirms MCL and directs MCL-specific therapy pathways [3].
• EBV-positive PTLD-type disease → supports a reduction-of-immunosuppression strategy [6].

Cell-of-origin increasingly intersects targeted approaches with differential activity by subtype, though its role remains an area of active refinement rather than a fixed gate [1,8].

Specimen and testing realities

Most lymphoma biomarkers are assessed on formalin-fixed, paraffin-embedded (FFPE) tissue from an excisional or core biopsy, because architecture and immunophenotype both matter. IHC (CD20, CD19, cyclin D1, SOX11, BCL2, MYC, MUM1, BCL6, CD10, Ki-67) and FISH (translocations, del(17p)) are the workhorses on tissue [1]. Flow cytometry on fresh tissue, blood, or marrow is valuable for surface antigen assessment, particularly CD20 and CD19. For CLL and WM, blood or marrow are the natural substrates for IGHV sequencing, MYD88 testing, and TP53 evaluation [7,11,14].

Molecular assays vary by target: allele-specific PCR or NGS for MYD88 L265P; NGS for TP53 mutations complementing FISH for del(17p); sequencing for IGHV. EBER in situ hybridization remains the standard for EBV detection, more reliable than LMP1 IHC alone [6].

Because certain results are diagnostically decisive, laboratories often build reflex testing algorithms — for example, cyclin D1 or SOX11 when a CD5-positive small B-cell lymphoma is suspected, or MYC FISH followed by BCL2 and BCL6 FISH when a high-grade morphology or high MYC IHC prompts double-hit workup. The dual-expressor-versus-double-hit distinction is a recurring interpretive pitfall that detail articles should make explicit: protein co-expression by IHC and genetic rearrangement by FISH are different tests with different meanings [9,15].

What's emerging (and moving fast)

Several areas are evolving and should be read as provisional. The therapeutic exploitation of cell-of-origin and other molecular subtypes of DLBCL continues to shift as agents with subtype-differential activity are studied [1,8]. Antigen-loss resistance to CD19-directed cellular and bispecific therapies is an active research front, raising interest in sequential and alternative-target strategies [13]. The boundaries of the high-grade B-cell lymphoma categories were redrawn in the 2022 classifications and remain under discussion, including the changed status of MYC/BCL6-only cases [2,15,16]. Finally, liquid-biopsy approaches (circulating tumor DNA) are advancing rapidly for detection, subtyping, and response monitoring, though within the records here tissue and marrow remain the validated substrates; this is a space to watch rather than a settled standard.

---

References

1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the WHO Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022. doi:10.1038/s41375-022-01620-2
2. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms. Blood. 2022. doi:10.1182/blood.2022015851
3. Jares P, et al. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Nuclear Cyclin D1 as Defining Features. Frontiers in Oncology / PMC7461610. 2020.
4. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009. PMID:19880778
5. Louissaint A Jr, Freedman AS, Lorsbach RB. Follicular lymphoma: updates for pathologists. Modern Pathology / PMC8743801. 2022.
6. Kanakry JA, et al. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients. 2015. PMID:26177728
7. Jimenez C, et al. Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and other B-cell non-Hodgkin lymphomas. PMC5054250. 2016.
8. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of DLBCL by immunohistochemistry using a tissue microarray. Blood. 2004. doi:10.1182/blood-2003-05-1545 (PMID:14695068)
9. Johnson NA, et al. Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2015. PMID:26421520
10. Hoster E, et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma. Journal of Clinical Oncology. 2016. PMID:26926679
11. Baliakas P, et al. IGHV mutational status and outcome for patients with chronic lymphocytic leukemia. Haematologica. 2020. PMC7271602
12. Weiner GJ. Anti-CD20 monoclonal antibodies: reviewing a revolution. Seminars in Hematology / PMC6343614. 2019.
13. CD19 CAR-T cell therapy for Relapsed or Refractory Diffuse Large B Cell Lymphoma; Why does it Fail? PMC10964476. 2024.
14. Huber H, et al. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut. 2023. PMID:37363867
15. Davies AJ. The high-grade B-cell lymphomas: double hit and more. Blood. 2024. doi:10.1182/blood.2023020780
16. Schmitz R, et al. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6. Blood / PMC5572137. 2017.